Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Parenthetical) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Total net revenue		$ 114,760	$ 116,275	$ 211,253	$ 223,717
Total cost of revenue	[1]	71,793	73,648	133,689	141,566
Research and development	[2]	14,641	14,697	28,733	29,079
Products
Total net revenue	[3]	63,269	60,721	107,892	113,480
Total cost of revenue		39,248	35,520	68,098	67,029
Services
Total net revenue	[4]	51,491	55,554	103,361	110,237
Total cost of revenue		32,545	38,128	65,591	74,537
Revenue from Joint Venture
Total cost of revenue		9,916	6,203	15,823	14,248
Research and development		487	415	1,266	994
Revenue from Joint Venture | Products
Total net revenue		16,715	8,816	25,584	14,735
Revenue from Joint Venture | Services
Total net revenue		$ 2,494	$ 2,679	$ 5,451	$ 5,494

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment, of $9,916 and $15,823 during the three and six months ended December 31, 2022, respectively, and $6,203 and $14,248 during the three and six months ended December 31, 2021, respectively.

[2] Includes charge back to the China joint venture, an equity method investment, related to a research and development project of $487 and $1,266 during the three and six months ended December 31, 2022, respectively, and $415 and $994 during the three and six months ended December 31, 2021, respectively.

[3] Includes sales to the China joint venture, an equity method investment, of $16,715 and $25,584 during the three and six months ended December 31, 2022, and $8,816 and $14,735 during the three and six months ended December 31, 2021, respectively. See Note 14.

[4] Includes sales to the China joint venture, an equity method investment, of $2,494 and $5,451 during the three and six months ended December 31, 2022, respectively, and $2,679 and $5,494 during the three and six months ended December 31, 2021, respectively. See Note 14.